Boston, MANCT06462183Now EnrollingIRB Ready

Adenoid Cystic Carcinoma Clinical Trial in Boston, MA

Access cutting-edge adenoid cystic carcinoma treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by Rgenta Therapeutics Inc

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access adenoid cystic carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related adenoid cystic carcinoma treatment provided free

Apply for This Boston Location

Check if you qualify for this adenoid cystic carcinoma clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Adenoid Cystic Carcinoma Study in Boston

Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC

Sponsor: Rgenta Therapeutics Inc

Who Can Participate

Inclusion Criteria

Histologically confirmed ACC or CRC
Radiographically measurable disease as assessed per RECIST 1.1, with at least 1 site of disease that is measurable and that has not been previously irradiated; or, if the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation
Patients with locally relapsed/refractory (R/R) advanced or metastatic ACC not amenable to potentially curative surgery or radiotherapy and progression of disease within 12 months at study entry
Patients with CRC must have locally R/R advanced or metastatic disease not amenable to potentially curative surgery or radiotherapy; must have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidines-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and if RAS wild-type, an anti-EGFR therapy.
Adequate hematologic status, organ function, renal function, liver function and prothrombin time (PT) or INR ≤ 1.5 × ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN
Resolved acute effects of any prior therapy to baseline

Exclusion Criteria

Major surgery or significant traumatic injury within 28 days prior to Cycle 1 Day 1
Chemotherapy within 14 days prior to Cycle 1 Day 1
Use of nitrosoureas or mitomycin C within 6 weeks prior to Cycle 1 Day 1
Radiation therapy within 21 days prior to Cycle 1 Day 1
Investigational drug use, targeted therapy, or biologic therapy within 28 days or 5 half-lives, whichever is shorter, prior to Cycle 1 Day 1
Ongoing systemic infection requiring treatment with antibiotic, antiviral, or antifungal treatment
Active known second malignancy
Clinically significant cardiac disease
Infection with human immunodeficiency virus (HIV)-1 or HIV-2 unless it's well-controlled HIV (eg, cluster of differentiation 4 \[CD4\] \> 350/mm3 and undetectable viral load)
Current active liver disease including hepatitis A (hepatitis A \[HepA\] virus immunoglobulin M \[IgM\] positive), hepatitis B (hepatitis B virus \[HBV\] surface antigen positive), or hepatitis C (hepatitis C virus \[HCV\] antibody positive, confirmed by HCV RNA)
Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant small bowel resection that would preclude adequate absorption
Uncontrolled diabetes
Treatment with a long-acting hematopoietic growth factor within 14 days before Cycle 1 Day 1 or a short-acting hematopoietic growth factor within 7 days before Cycle 1 Day 1
Treatment with high-dose chemotherapy and stem-cell rescue (autologous stem cell transplant) or allogeneic stem cell transplant within 90 days before Cycle 1 Day 1
Patients with central nervous system (CNS) metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroid throughout this indication for at least 4 weeks before starting treatment in this study
History of solid organ transplantation
Coronavirus disease 2019 (COVID-19) vaccination within 14 days prior to first dose of study drug
Prior treatment with a MYB inhibitor

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT06462183) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Adenoid Cystic Carcinoma Treatment Options in Boston, MA

If you're searching for adenoid cystic carcinoma treatment options in Boston, MA, this clinical trial (NCT06462183) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced adenoid cystic carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all adenoid cystic carcinoma clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Boston, MA

See all alzheimers disease clinical trials recruiting in Boston — not just this study.

Browse Alzheimers Disease Trials in Boston →

Browse More Trials by Condition

Alzheimers Disease TrialsAtopic Dermatitis TrialsInterstitial Cystitis TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA